REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
REGENERON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$782.04−8.70 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $82.90B
- P/E (TTM)
- 19.3
- Dividend yield
- –
REGENERON PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $8.29B | $7.70B | $7.33B | $6.97B | $6.66B | $6.32B | $6.06B | $5.82B | $5.60B | $5.39B | $5.50B | $5.72B | 53.4% | +24.6% |
| Net product sales | $6.44B | $6.43B | $6.31B | $6.64B | $7.00B | $7.28B | $7.63B | $7.48B | $7.32B | $7.17B | $7.08B | $6.93B | 41.5% | -8.0% |
| Libtayo | $1.72B | $1.61B | $1.45B | $1.39B | $1.32B | $1.24B | $1.22B | $1.09B | $1.04B | $950.10M | $863.10M | – | 11.1% | +30.5% |
| Other revenue | $801.30M | $791.90M | $702.60M | $643.40M | $559.40M | $480.00M | $515.00M | $548.10M | $572.20M | $537.00M | $536.10M | $451.30M | 5.2% | +43.2% |
| Other products | $41.40M | $41.40M | $10.10M | $800.00K | $0 | – | $0 | – | – | – | – | – | 0.3% | – |
By region
From the segment and revenue-disaggregation notes of Regeneron Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.